...
首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Elevated p53 promotes the processing of miR-18a to decrease estrogen receptor-alpha in female hepatocellular carcinoma
【24h】

Elevated p53 promotes the processing of miR-18a to decrease estrogen receptor-alpha in female hepatocellular carcinoma

机译:升高的P53促进miR-18a的处理减少雌性肝细胞癌中的雌激素受体-α

获取原文
获取原文并翻译 | 示例

摘要

The estrogen pathway has long been implicated as a tumor protector in female hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Our previous study identified that estrogen receptor alpha (ER) protein is downregulated in 60% of female HCC cases, via a miR-18a elevation mediated suppression of ER translation. This study aims to delineate the mechanism underlying the upregulation of miR-18a in female HCC. The analysis of 77 female HCC specimens revealed that miR-18a levels were associated with pre-miR-18a rather than pri-miR-18a levels, suggesting an enhanced processing of pri- to pre-miR-18a. Among a panel of factors involved in microRNA processing, p53 was identified as a novel regulator for miR-18a maturation process. Knockdown of p53 by si-RNA decreased the level of miR-18a, whereas overexpression of either wild-type or mutant p53 increased its level. The association between the elevation of miR-18a and the accumulation of p53, mainly caused by somatic mutations, was confirmed in the clinical specimens of HBV-related female HCC. By analyzing the association with clinicopathological features, activation of this p53/miR-18a pathway mainly occurs in younger or noncirrhosis female HCC patients and associated with a trend of worse overall survival. Therefore, this study demonstrated a novel function of elevated/mutant p53 in regulating the amount of ER protein through its promoting the biogenesis of miR-18a, which could lead to decrease the tumor-protective function of the estrogen pathway in female hepatocarcinogenesis.
机译:雌激素途径长期以来涉及雌性乙型肝炎病毒(HBV)的肿瘤保护剂 - 相关的肝细胞癌(HCC)。我们以前的研究发现,雌激素受体α(ER)蛋白在60%的雌性HCC病例中下调,通过MIR-18A升降介导的ER翻译抑制。本研究旨在描绘雌性HCC中miR-18a的上调潜在的机制。对77例雌性HCC标本的分析表明,miR-18a水平与前miR-18a而不是pri-miR-18a水平相关,表明PRI-pre-miR-18a的增强加工。在参与MicroRNA处理的因素中,P53被鉴定为MIR-18A成熟过程的新型调节剂。通过Si-RNA的P53敲低下降了miR-18a的水平,而野生型或突变体P53的过度表达增加了其水平。在HBV相关的雌性HCC的临床标本中证实了MIR-18A的升高和P53的积累之间的关联,主要是由体细胞突变引起的。通过分析与临床病理学特征的关联,该P53 / miR-18A途径的激活主要发生在较年轻或非鼠年鼠雌性HCC患者中,与总体存活率更严重的趋势相关。因此,本研究证明了通过其促进miR-18a的生物发生来调节ER蛋白的量的升高/突变体P53的新功能,这可能导致雌性肝癌发生中雌激素途径的肿瘤保护功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号